PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7903237

Schizophrenia: advances in its basic biology.

H K arap Mengech
View original source ↗Export metadata ↓

Abstract

Some recent work on possible biochemical aetiological factors in schizophrenia are reviewed in this paper. For over 80 years, research workers have searched diligently for biological disorders in schizophrenia and it was only in the last thirty or so years that encouraging results have been presented. It is now believed that some genetically determined factors, mediated through the dopaminergic pathways in the brain are responsible for schizophrenic symptomatology. Specific dopaminergic pathways are thought to be responsible for some of the specific clinical features of schizophrenia.

Explore related subjects

Antipsychotic AgentsBiological PsychiatryDopamineHistory, 20th CenturyHumansSchizophreniaHistorical ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H K arap Mengech. 1993. Schizophrenia: advances in its basic biology.. https://pubmed.ncbi.nlm.nih.gov/7903237/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗